Late-phase impact of CMV/EBV reactivation on survival after hematopoietic stem-cell transplantation: a 5-year single-center cohort study.

Front Cell Infect Microbiol · 2026 · PMC13058802 · PMID 41959562

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.1160

boldest claim

The sentences

approaching significancep = 0.051so close (0.05 < p ≤ 0.1)

While 1-year OS and LFS were comparable across groups ( p < 0.2), the gap widened progressively thereafter; by 3 years, patients with CMV/EBV coreactivation showed the lowest OS (20.3%) and LFS (19.3%), with the OS difference approaching significance ( p = 0.051) and LFS already significant ( p = 0.028).

also in 2,640 other papers

a strong trendp = 0.056so close (0.05 < p ≤ 0.1)

GVHD showed a strong trend toward adverse LFS (HR 2.46, p = 0.056), whereas coreactivation and isolated CMV reactivation carried HRs of approximately 1.2 relative to the no-reactivation group, but neither reached statistical significance ( p ≥ 0.7).

also in 5,725 other papers

a nonsignificant trendp = 0.116not close (p > 0.1)

Of note, patients who later developed CMV/EBV coreactivation received significantly lower MNC counts (8.60 vs 8.95 × 10 8 /kg; p = 0.041), whereas CD34 + content showed only a nonsignificant trend toward reduction (1.78 vs 2.53 × 10 6 /kg; p = 0.116).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.